Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSAzilsartan medoxomil is a prodrug form of azilsartan (Item No. 26091), a potent and selective angiotensin II receptor 1 (AT1) antagonist.1,2 Azilsartan medoxomil (0.1-10 mg/kg) reduces blood pressure and decreases plasminogen activator inhibitor 1 (PAI-1) levels in the plasma, left ventricle, and aortic wall in mice in a dose-dependent manner.2 It also inhibits the pressor response induced by angiotensin II (Item No. 17150) in normotensive rats (ID50 = 0.12 mg/kg) and reduces blood pressure and improves glucose infusion, a marker of insulin sensitivity, in spontaneously hypertensive rats.3 Azilsartan medoxomil also has more potent antiproteinuric effects in Wistar fatty rats than olmesartan medoxomil (Item No. 11614). Formulations containing azilsartan medoxomil have been used in the treatment of hypertension.
WARNING This product is not for human or veterinary use.
1. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J. Pharmacol. Exp. Ther. 336(3), 801-808 (2011).
2. The angiotensin receptor blocker, azilsartan medoxomil (TAK-
3. Antihypertensive, insulin-